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7LETTER TO THE EDITOR
cute Hemolysis in a Patient with Cytomegalovirus
neumonitis Treated with Intravenous
mmunoglobulin (IVIG)
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OWe present a case of intravenous immunoglobulin
IVIG)-associated intravascular hemolysis. A 52-year-
ld woman with a history of multiple myeloma was
dmitted for management of presumed cytomegalovi-
us (CMV) pneumonia. The patient had previously
ndergone an autologous stem cell transplantation
ith high-dose melphalan (200 mg/m2) followed by a
andem nonmyeloablative allogeneic transplant 3
onths later with ﬂudarabine/cyclophosphamide con-
itioning and tacrolimus plus low-dose methotrexate
or graft-versus-host disease prophylaxis. Full donor
himerism was established by day 60 after allografting,
nd she did not require donor lymphocyte infusions at
ny time. She was seropositive for CMV immuno-
lobulin G (IgG) before transplantation and received
graft from her CMV-positive, ABO-compatible sib-
ing (donor type A, recipient type O). The patient
as 406 days removed from the allogeneic portion of
he protocol, and her multiple myeloma remained in a
omplete remission. Four weeks before the current
dmission, the patient developed an unremitting, non-
roductive cough, and a quantitative CMV polymer-
se chain reaction was found to be positive at 1654
opies/mL. Despite a month of valganciclovir therapy,
er CMV viral load remained positive and her pulmo-
ary status failed to improve, prompting this admis-
ion for further management.
On hospital day 1 intravenous ganciclovir was ini-
iated at a dose of 5 mg/kg every 12 hours, and on
ospital day 4 IVIG (Gamunex,Talecris Pharmaceu-
icals, Research Triangle Park, NC) was initiated at a
aily dose of 500 mg/kg. The patient received 5 doses
f IVIG (2.5 g/kg) from days 4 through 8. Each dose
f immunoglobulin was identical and consisted of a
ixture of IVIG obtained from 3 separate lots. On
ospital day 8, the patient’s urine became tea-colored.
he following morning she exhibited gross hemo-
lobinuria, with 4 blood by urinalysis but only 1
ed blood cell (RBC)/high-power ﬁeld on micro-
copic examination. Additional laboratory studies
emonstrated that the patient’s hemoglobin had
ecreased from 13.1 g/dL on hospital day 1 to 9.1
/dL on day 9, serum lactate dehydrogenase had c
86ncreased to 6000 U/L (normal, 338-610), serum
ilirubin had increased to 2.1 mg/dL, and the cir-
ulating nucleated RBC count had increased to 97
er 100 white blood cells (Table 1). Haptoglobin
as undetectable. Direct and indirect Coombs tests
ent on day 9 were negative.
Because the hemoglobinuria appeared to coincide
ith administration of IVIG, we speciﬁcally searched
or the presence of an anti-A immunoglobulin. A re-
eat direct Coombs test sample sent on hospital day
0 was weakly positive for IgG, which, when eluted,
as reactive with A RBCs. One week before this
dmission, the patient had typed A with a negative
ntibody screen against group O cells. The anti-A in
he patient’s serum and in each of the 3 lots of IVIG
he received was titered in saline. After incubation for
0 minutes at room temperature, titers were 1:1 for all
VIG lots and 1:4 for the patient. When titers were
arried through the anti-human globulin phase, all
VIG lots subsequently titered 1:32.
Over the course of the next several weeks, the
atient gradually improved from a pulmonary and
ematologic standpoint. Her lactate dehydrogenase,
erum bilirubin, and nucleated RBC count slowly re-
urned to baseline levels, and a repeat direct antiglob-
lin test (DAT) sent approximately 8 weeks after the
atient’s discharge was negative for anti-A.
Based on our patient’s new hemoglobinuria, de-
reased serum hemoglobin, undetectable haptoglobin,
ncreased lactate dehydrogenase, and new transfusion
ependence for the ﬁrst time since receiving her allo-
eneic transplant, we were conﬁdent that she was
emonstrating signs of signiﬁcant intravascular hemo-
ysis. However, the etiology was not immediately ob-
ious, particularly in light of the initially negative
AT. Thrombotic thrombocytopenic purpura was
uled out by the absence of thrombocytopenia and the
ack of schistocytes on the peripheral smear. The pa-
ient’s medications were reviewed carefully and no
ew pharmacologic cause was identiﬁed. The patient’s
riginal ABO blood type before transplantation was
 and her matched sibling donor was A. One
onsideration was that the patient might have been
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Letter to the Editor 787emonstrating evidence of graft rejection, with host
ymphocytes mounting an immune response against
foreign” donor erythrocytes. However, chimerism
tudies conﬁrmed that the patient continued to exhibit
omplete donor reconstitution to the limits of our
ssay.
A careful review of the patient’s laboratory data
uggested that she was showing signs of mild hemo-
ysis during the ﬁrst several days of her admission,
efore any new medications were administered. On
ospital day 1, lactate dehydrogenase was increased to
112 U/L; on day 2, the reticulocyte count was
62.4  109 cells/L (normal, 25-75), with 4 nucleated
BCs/100 white blood cells seen on the peripheral
lood smear (Table 1). One month before this hospi-
alization, the patient had demonstrated no circulating
ucleated RBCs, and previous reticulocyte counts
rawn after allogeneic transplantation had been within
ormal limits. Acute CMV infection has been associ-
ted with episodes of hemolysis, presumably due to
ntiviral IgM antibodies reacting with protein anti-
ens on the surface of RBCs [1,2]. Therefore, the
MV infection itself may have resulted in a subclinical
emolysis before this hospital admission. Neverthe-
ess, the time course of the patient’s hemoglobinuria
nd the dramatic worsening of hemolysis (to the point
hat she became transfusion dependent) after IVIG
dministration strongly suggested that the immuno-
lobulin infusion exacerbated any preexisting RBC
estruction that may have been present. Moreover,
ur detection of a new anti-A IgG after IVIG infusion
which was also present in all of the immunoglobulin
ots that the patient received) provided further evi-
able 1. Pertinent Laboratory Values by Hospital Day*
1 2 3 4 5
anciclovir X X X X X
VIG X X
ransfused†
emoglobinuria
BC (109/L) 9.2 8.4 7.8 7.2 9
gb (g/dL) 13.1 12.4 11.9 11.5 11
ct (%) 41.6 38.3 36.7 36.0 35
CV (FL) 65 64 65 64 64
latelets (109/L) 146 130 130 128 134
ucleated RBC/100 WBC 5 4 6 5 3
eticulocytes (109/L; nl
<75/L) 162
DH (U/L)‡§ 1112 938 1215
ilirubin (mg/dL)‡ 0.4 0.3
irect Coombs test
WBC indicates white blood cell; Hgb, hemoglobin; Hct, hemato
hemolyzed.
The patient was transfused with 2 U of type O packed RBCs on h
Laboratory results are listed for every day that they were drawn.
On these days, an LDH was not performed because blood sample
Laboratory values were drawn in clinic 3 months after hospitalizaence that IVIG contributed to the patient’s anemia. aIVIG is a collection of pooled polyclonal human
mmunoglobulin derived from the plasma of up to
000 different donors. IVIG may contain immuno-
lobulin directed against 1 of the major blood group
ntigens, and transfusion reactions are possible when
dministered to recipients with A, B, and AB blood
ypes. Such reactions, although uncommon, have been
eported in the medical literature [3]. In this patient,
e observed evidence of hemoglobinuria 4 days after
he ﬁrst dose of IVIG was administered. We suspect
hat our patient’s passively acquired IVIG was able to
otentiate a strong, intravascular hemolytic reaction
or several reasons. First, IVIG efﬁciently ﬁxes com-
lement in vivo [4]. This property has been proposed
s a possible mechanism of action for its therapeutic
mmunomodulating effects. It is thought that ﬂuid-
hase IVIG binds activated complement components
nd scavenges them away from vulnerable cell surface
argets [5]. Second, the A carbohydrate antigen is
xpressed at extremely high levels on the erythrocyte
urface, on the order of 1.6 106 antigens per cell [6].
hird, although the IVIG lots in question did not
ontain especially high concentrations of anti-A anti-
ody, the total dose of immunoglobulin that was ad-
inistered (175 g) was sizeable and exceeded that
ypically produced in vivo under physiologic condi-
ions. The very weak direct Coombs test results were
ikely related to the effective and rapid clearance of the
atient’s group A RBCs. Only those cells with low
evels of bound antibody remained viable in the cir-
ulation long enough to be detected by DAT.
Because IVIG is used frequently in clinical prac-
ice, it is not clear why brisk hemolysis occurs in only
Hospital Day
7 8 9 10 11 12 3 mo
X X X X X X
X X
X
X X X X X
.8 5.6 7.2 5.1 7.8 7.7 6.1 8.6
.5 10.5 10.2 9.1 8.3 10.5 9.7 10
.8 32.6 29.6 26.8 24.1 29.8 27.6 31.5
62 61 61 62 68 68 89
120 123 133 169 167 170 178
36 22 97 64 79 70 4
H H H 6286 792
0.3 1.6 2.1 0.3
Negative Positive
CV, mean corpuscular volume; LDH, lactate dehydrogenase; H,
day 11 before laboratory values from that morning were collected.
so extensively hemolyzed.6
X
X
.7 4
.7 11
.9 34
63
118
13
140
crit; M
ospital
s wereminority of patients with A, B, or AB blood types.
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Letter to the Editor788ifferent IVIG lots contain variable amounts of
nti-A and anti-B immunoglobulins. It has been sug-
ested that IVIG lots containing anti-A titers 1:16
re more likely to result in clinical hemolysis than are
hose with lower antibody concentrations [3]. Our
VIG lots titered 1:32 for anti-A using an anti-human
lobulin phase method.
In summary, IVIG can result in signiﬁcant intra-
ascular hemolysis due to passively acquired ABO an-
ibodies. This complication is not easily predictable
nd underscores the need for careful monitoring of
atients after IVIG administration. A potent hemoly-
in such as an anti-A may be difﬁcult to detect, and a
igh index of suspicion is needed to recognize IVIG-
ediated RBC destruction. This is particularly true in
atients after stem cell transplantation in whom
olypharmacy and infections can confound the clinical
icture.
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